Director, Oncology Antibody Conjugates
"If you have a great idea, people and resources will follow. The challenge is yours to provide compelling data and strategy to support your idea."
years at Genentech
awards & honors
I joined Genentech in 2004 to lead a team focused on antibody drug-conjugates for B cell malignancies and ever since I arrived, I have felt challenged and privileged to work with an elite group of scientists, clinicians, and manufacturing colleagues. Genentech does a terrific job of ensuring new projects are aimed at making a competitive molecule that will be meaningful to patients. Success is never certain, but compelling data are their own reward, and I found the challenges of opening up a new therapeutic platform around antibody-drug conjugates very satisfying. When I look at the proportion of our pipeline represented by the antibody-drug conjugates and their clinical potential, I feel these efforts were a great career opportunity and it’s been exciting to watch these three molecules advance in the clinic.
My lab also worked for several years to evaluate the therapeutic potential of PI3K inhibition in hematologic malignancies and in 2007 we leveraged these knowledge and experience to initiate a project around the PIM kinases which share certain functions with the PI3K pathway. Although Genentech never advanced a PI3K inhibitor in heme-onc, it is nonetheless satisfying to see our preclinical data on PI3K inhibition validated in the clinic through the work of others, and the PIM project has continued to advance with a deep knowledge of mechanism and PD biomarkers. We are excited, in particular, by the data being generated on our PIM inhibitors in multiple myeloma.
In 2011 we formalized my department of Cancer Immunology and Hematology around a group of six labs already working in these areas. We have an extraordinary diversity of approaches and technologies being applied to the problem. It's great to work in an organization with expertise and ability in so many different technology platforms including conventional antibodies, antibody-drug conjugates, bispecific antibodies, and small molecule inhibitors- they all have a place in our department's portfolio. This tool set, coupled with different approaches that aim to stimulate the immune system and aim to overcome immunosuppression, provides an unparalleled opportunity for clinical discovery.
Conjugation site modulates the in vivo stability and therapeutic activity of antibody conjugates
Nature Biotechnology in press 2012
Shen B-Q, Xu K, Liu L, Raab H, Bhakta S, Kenrick M, Parsons K, Tien J, Yu S-F, Mai E, Li D, Tibbitts J, Baudys J, Saad O, Scales S, McDonald P, Hass P, Eigenbrot C, Nguyen T, Solis W, Fuji R, Flagella K, Patel D, Spencer S, Khawli L, Ebens A, Wong W, Vandlen R, Kaur S, Sliwkowski M, Scheller R, Polakis P, Junutula J
View Abstract on PubMed
As an organization, we are very proud of the impact that we've had in the hematologic malignancies. One of my focus areas is to see that we continue to improve and extend progress in lymphoma, leukemia, and multiple myeloma by coordinating our research efforts with other functional areas and continuing to evaluate new opportunities and propose new potential targets and programs in these therapeutic areas. More recently, I've been immersed in Immunology. I'm humbled by the breadth and depth of the communities' knowledge of the immune system, and fortunate to have many excellent colleagues as teachers and advisors.
The Pim-1 Protein Kinase Is an Important Regulator of MET Receptor Tyrosine Kinase Levels and SignalingJournal of molecular and cellular biology, 2014, ISSN: 0270-7306 View on PubMed
Discovery of novel pyrazolo1,5-apyrimidines as potent pan-Pim inhibitors by structure- and property-based drug designBioorganic & Medicinal Chemistry Letters, 2013, ISSN: 0960-894X View on PubMed
Development of a robust flow cytometry-based pharmacodynamic assay to detect phosphoprotein signals for phosphatidylinositol 3-kinase inhibitors in multiple myelomaJournal of Translational Medicine, 2013, ISSN: 1479-5876 View on PubMed
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugatesNature Biotechnology, 2012, ISSN: 1087-0156 View on PubMed
Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphomaLeukemia, 2010, ISSN: 1476-5551 View on PubMed
CD40 Pathway Activation Status Predicts Response to CD40 Targeted Therapy in Diffuse Large b-Cell Lymphoma.Blood, 2009, ISSN: 0006-4971
FcRL5 as a Target of Antibody-Drug Conjugates for the Treatment of Multiple Myeloma.Blood, 2009, ISSN: 0006-4971
The PI3K Inhibitor GDC-0941 Induces Growth Arrest and Apoptosis of Acute Myeloid Leukemia Cells.Blood, 2009, ISSN: 0006-4971
The PI3K Inhibitor GDC-0941 Synergizes with Standard of Care Therapies to Induce Growth Inhibition and Apoptosis of Multiple Myeloma Cells.Blood, 2009, ISSN: 0006-4971
In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates.Molecular Cancer Therapeutics, 2009, ISSN: 1538-8514
Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin's lymphoma.Blood, 2009, ISSN: 1528-0020
Antibody-drug conjugates for the treatment of Non-Hodgkin's Lymphoma: target and linker-drug selection.Cancer Research, 2009, ISSN: 1538-7445
- University of California, San Francisco, Postdoctral Fellow – 1997
- University of California, Los Angeles, Molecular Biology, Ph.d – 1995
- University of Washington, Chemistry, B.Sc. – 1989
Awards & Honors
- American Cancer Society Postdoctoral Fellowship – 1995-1997
- Neurobiology Scholarship – 1993
- NIH Predoctoral National Research Service Award – 1993-1995